<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We analyzed pretherapeutic gene expression patterns of patients with locally advanced <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> of the esophagus with regard to response to neoadjuvant chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: Pretherapeutic, paraffin-embedded, formalin-fixed endoscopic <z:e sem="disease" ids="C0014859" disease_type="Neoplastic Process" abbrv="">esophageal tumor</z:e> biopsies of 38 patients with locally advanced esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> (Barrett <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>) were included </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent two cycles of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) therapy with or without additional paclitaxel followed by abdominothoracal esophagectomy </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi> expression levels of 5-FU metabolism-associated genes thymidylate synthase, <z:chebi fb="0" ids="17748">thymidine</z:chebi> phosphorylase, dihydropyrimidine dehydrogenase, <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase, MAP7, and ELF3, of <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>- and <z:chebi fb="0" ids="36064">taxane</z:chebi>-related genes caldesmon, ERCC1, ERCC4, HER-2/neu, and GADD45, and of multidrug resistance gene MRP1 were determined using real-time reverse transcriptase-PCR </plain></SENT>
<SENT sid="4" pm="."><plain>Expression levels were correlated with response to chemotherapy, histopathologically assessed in surgically resected specimens </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Responding patients showed significantly higher pretherapeutic expression levels of MTHFR (P = 0.012), caldesmon (P = 0.016), and MRP1 (P = 0.007) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, patients with high pretherapeutic MTHFR and MRP1 levels had a survival benefit after surgery (P = 0.013 and P = 0.015, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Additionally, investigation of intratumoral <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of gene expression of relevant genes (MTHFR, caldesmon, HER-2/neu, ERCC4, and MRP1), verified in nine untreated Barrett <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> by examination of five distinct <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> areas, revealed no significant <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in gene expression indicating that expression profiles obtained from biopsy material may yield a representative genetic expression profile of total <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our results indicate that determination of <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of few genes may be useful for the prediction of the success of neoadjuvant chemotherapy in individual <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients with locally advanced Barrett <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>